search
Back to results

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (ADDRESS+)

Primary Purpose

Pemphigus Vulgaris, Pemphigus Foliaceus

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
efgartigimod PH20 SC
prednisone
Sponsored by
argenx
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pemphigus Vulgaris

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Ability to understand the requirements of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), willingness and ability to comply with the trial protocol procedures (including required trial visits).
  2. The participant participated in trial ARGX-113-1904 and completed the study or has the defined criteria for rollover.

  3. Contraceptive use by men and women should be consistent with local regulations regarding the methods for contraception for those participating in clinical trials and:

    1. Male participants:

      Male participants must agree to use an acceptable method of contraception as described in the protocol, from signing the ICF until the last dose of the study drug.

    2. Female participants

Women of childbearing potential (WOCBP) must:

  • have a negative urine pregnancy test at baseline before the IMP can be administered,
  • agree to use a highly effective or acceptable contraception method (as described in the protocol), which should be maintained at minimum until after the last dose of IMP

Exclusion Criteria:

  1. Pregnant and lactating women and those intending to become pregnant during the trial.
  2. Participants with clinical evidence of other significant serious disease or participants who recently underwent or have planned a major surgery during the period of the trial, or any other condition in the opinion of the investigator, that could confound the results of the trial or put the participant at undue risk.
  3. Known hypersensitivity to any of the components of the administered treatments.

Sites / Locations

  • Investigator site 115 - US0010086Recruiting
  • Investigator site 89 - US0010091Recruiting
  • Investigator site 124 - US0010092Recruiting
  • Investigator site 1 - US0010087Recruiting
  • Investigator site 90 - US0010117Recruiting
  • Investigator site 91 - US0010109
  • Investigator site 126 - US0010090
  • Investigator site 111 - US0010098Recruiting
  • Investigator site 10 - US0010088Recruiting
  • Investigator site 76 - US0010096Recruiting
  • Investigator site 30 - US0010094
  • Investigator site 84 - US0010089
  • Investigator site 103 - US0010097Recruiting
  • Investigator site 125 - US0010107
  • Investigator site 87 - US0010084
  • Investigator site 88 - US0010114
  • Investigator site 44 - US0010106
  • Investigator site 15 - AU0610006Recruiting
  • Investigator site 11 - AU0610007Recruiting
  • Investigator site 92 - AU0610013
  • Investigator site 17 - BG3590012
  • Investigator site 18 - BG3590013
  • Investigator site 2 - BG3590010Recruiting
  • Investigator site 16 - BG3590009
  • Investigator site 3 - BG3590011Recruiting
  • Investigator site 101 - CN0860017Recruiting
  • Investigator site 107 - CN0860018Recruiting
  • Investigator site 118 - CH0860027Recruiting
  • Investigator site 120 - CH0860023Recruiting
  • Investigator site 119 - CH0860022
  • Investigator site 116 - CH0860053
  • Investigator site 100 - CN0860021Recruiting
  • Investigator site 113 - CN0860024
  • Investigator site 102 - CN0860020Recruiting
  • Investigator site 99 - CN0860016
  • Investigator site 112 - CN0860019Recruiting
  • Investigator site 121 - CH0860025
  • Investigator site 117 - CH0860026Recruiting
  • Investigator site 77 - FR0330028Recruiting
  • Investigator site 60 - FR0330027Recruiting
  • Investigator site 108 - FR0330029Recruiting
  • Investigator site 51 - FR0330026Recruiting
  • Investigator site 78 - GE9950014Recruiting
  • Investigator site 127 - GE9950030Recruiting
  • Investigator site 32 - GE9950013
  • Investigator site 31 - GE9950015Recruiting
  • Investigator site 45 - DE0490029
  • Investigator site 34 - DE0490030Recruiting
  • Investigator site 33 - DE0490024Recruiting
  • Investigator site 53 - DE0490023Recruiting
  • Investigator site 35 - DE0490028Recruiting
  • Investigator site 20 - DE0490002
  • Investigator site 52 - DE0490001Recruiting
  • Investigator site 19 - DE0490025
  • Investigator site 93 - DE0490027
  • Investigator site 4 - DE0490026Recruiting
  • Investigator site 21 - GR030004Recruiting
  • Investigator site 37 - GR030006Recruiting
  • Investigator site 54 - GR0300001Recruiting
  • Investigator site 22 - GR030003Recruiting
  • Investigator site 36 - GR0300002
  • Investigator site 23 - GR030005Recruiting
  • Investigator site 6 - HU0360003Recruiting
  • Investigator site 5 - HU0360001
  • Investigator site 24 - HU0360002
  • Investigator site 65 - IN0910002Recruiting
  • Investigator site 94 - IN0910001Recruiting
  • Investigator site 79 - IN0910004Recruiting
  • Investigator site 80 - IN0910003Recruiting
  • Investigator site 85 - IL9720002
  • Investigator site 95 - IT0390039Recruiting
  • Investigator site 38 - IT0390031Recruiting
  • Investigator site 81 - IT0390030Recruiting
  • Investigator site 55 - IT0390038
  • Investigator site 12 - IT0390006Recruiting
  • Investigator site 25 - IT-0390005Recruiting
  • Investigator site 61 - IT0390040Recruiting
  • Investigator site 82 - JP0810046
  • Investigator site 68 - JP0810040Recruiting
  • Investigator site 69 - JP0810050Recruiting
  • Investigator site 66 - JP0810042Recruiting
  • Investigator site 73 - JP0810047
  • Investigator site 70 - JP0810041Recruiting
  • Investigator site 71 - JP0810049Recruiting
  • Investigator site 72 - JP0810045Recruiting
  • Investigator site 114 - JP0810067Recruiting
  • Investigator site 67 - JP0810043Recruiting
  • Investigator site 27 - PL0480027Recruiting
  • Investigator site 86 - PL0480036
  • Investigator site 28 - PL0480025Recruiting
  • Investigator site 26 - PL0480028Recruiting
  • Investigator site 56 - PL0480032Recruiting
  • Investigator site 97 - RO0400013Recruiting
  • Investigator 96 - RO0400014
  • Investigator site 98 - RO0400015Recruiting
  • Investigator site 40 - RU0070035
  • Investigator site 41 - RU0070033Recruiting
  • Investigator site 48 - RU0070029
  • Investigator site 49 - RU0070030Recruiting
  • Investigator site 39 - RU0070032Recruiting
  • Investigator site 46 - RU0070031Recruiting
  • Investigator site 50 - RU0070034Recruiting
  • Investigator site 47 - RU0070028
  • Investigator site 109 - RS3810011
  • Investigator site 110 - RS3810010
  • Investigator site 105 - RS3810012
  • Investigator site 104 - RS3810009Recruiting
  • Investigator site 62 - ES0340026
  • Investigator site 13 - ES0340032Recruiting
  • Investigator site 122 - ES0340053Recruiting
  • Investigator site 59 - ES0340034
  • Investigator site 42 - ES0340025
  • Investigator site 7 - ES0340029Recruiting
  • Investigator site 57 - ES0340027
  • Investigator site 58 - ES0340028
  • Investigator site 64 - TR0900020
  • Investigator site 63 - TR0900012Recruiting
  • Investigator site 74 - TR0900011
  • Investigator site 75 - UA3800017Recruiting
  • Investigator site 29 - UA3800023Recruiting
  • Investigator site 14 - UA3800020
  • Investigator site 8 - UA3800019Recruiting
  • Investigator site 43 - UA3800021Recruiting
  • Investigator site 9 - UA3800018Recruiting
  • Investigator site 106 - UK0440021
  • Investigator site 83 - UK0440022Recruiting
  • Investigator site 123 - UK0440037

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

efgartigimod PH20 SC

Arm Description

patients receiving efgartigimod PH20 SC on top of prednisone

Outcomes

Primary Outcome Measures

Incidence of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE)
Incidence of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE)
Severity of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE)
Severity of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE)

Secondary Outcome Measures

Proportion of Pemphigus Vulgaris (PV) participants who achieve complete clinical remission (CR) on minimal prednisone therapy
Proportion of participants with Pemphigus Vulgaris who achieve complete clinical remission on minimal prednisone therapy.
Proportion of Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) participants who achieve complete clinical remission (CR) on minimal prednisone dose therapy
Proportion of participants with Pemphigus Vulgaris and Pemphigus Foliaceus who achieve complete clinical remission on minimal prednisone therapy.
Time to Disease Control (DC)
Time to Disease Control
Time to complete clinical remission (CR)
Time to complete clinical remission
Time to complete clinical remission (CR) on minimal prednisone therapy
Time to complete clinical remission on minimal prednisone therapy
Time to complete clinical remission (CR) off prednisone therapy
Time to complete clinical remission off prednisone therapy
Time to flare
Time to flare
Rate of treatment failure
Rate of treatment failure
Rate of flare
Rate of flare
Cumulative prednisone dose over the trial
Cumulative prednisone dose over the trial
Pemphigus Disease Area Index (PDAI) at each visit
Pemphigus Disease Area Index at each visit
EuroQol 5-Dimension 5-Level (EQ-5D-5L) score
EuroQol 5-Dimension 5-Level score
Autoimmune Blister Quality of Life (ABQOL) score
Autoimmune Blister Quality of Life score
Efgartigimod serum concentrations
Efgartigimod serum concentrations
Total Immunoglobulin G and subtype (IgG1, IgG2, IgG3, IgG4) serum levels
Total Immunoglobulin G and subtype (IgG1, IgG2, IgG3, IgG4) serum levels
Anti-desmoglein (Dsg) -1 and -3 autoantibodies serum levels
Anti-desmoglein (Dsg) -1 and -3 autoantibodies serum levels
Incidence of antidrug antibodies (ADA) against efgartigimod PH20 SC
Incidence of antidrug antibodies (ADA) against efgartigimod PH20 SC
Prevalence of antidrug antibodies (ADA) against efgartigimod PH20 SC
Prevalence of antidrug antibodies (ADA) against efgartigimod PH20 SC
Composite Glucocorticoid Toxicity Index (C-GTI) comprising the Aggregate Improvement Score (AIS) and the Cumulative Worsening Score (CWS)
Composite Glucocorticoid Toxicity Index comprising the Aggregate Improvement Score and the Cumulative Worsening Score
Percentage of participants who performed self-administration
Percentage of participants who performed self-administration
Percentage of caregivers who administered the injection to the participant
Percentage of caregivers who administered the injection to the participant
Number of visits needed for the participant or caregiver to be competent to start administering efgartigimod PH20 SC
Number of visits needed for the participant or caregiver to be competent to start administering efgartigimod PH20 SC
Frequency of self- or caregiver-supported administration at home
Frequency of self- or caregiver-supported administration at home

Full Information

First Posted
October 8, 2020
Last Updated
May 2, 2023
Sponsor
argenx
search

1. Study Identification

Unique Protocol Identification Number
NCT04598477
Brief Title
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
Acronym
ADDRESS+
Official Title
An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Pemphigus
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 15, 2021 (Actual)
Primary Completion Date
September 24, 2024 (Anticipated)
Study Completion Date
November 19, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
argenx

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a prospective, multicenter, open label extension (OLE) trial on the efficacy, safety, patient outcome measures, tolerability, immunogenicity, PK and PD of efgartigimod PH20 SC in adult PV or PF participants, who participated in antecedent trial ARGX-113-1904. This trial provides extension of efgartigimod PH20 SC treatment and retreatment options for participants who have been randomized to efgartigimod PH20 SC treatment arm in the trial ARGX-113-1904, and the first treatment of efgartigimod PH20 SC and retreatment options for participants who had been randomized to placebo arm in trial ARGX-113-1904. Trial ARGX-113-1905 evaluates ability to (further) taper prednisone therapy and achieve Clinical Remission (CR) off therapy (CRoff), the ability to achieve CR and CR on minimal therapy (CRmin) for participants who had not yet achieved CRmin, and the ability to treat flare; and assess patient outcome measures and the safety, PD, PK and immunogenicity of efgartigimod PH20 SC over the duration of trial. Study duration: Up to 60 weeks for participants who receive IMP administration up to 52 weeks and with a follow-up period of 8 weeks after the last IMP administration

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pemphigus Vulgaris, Pemphigus Foliaceus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
213 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
efgartigimod PH20 SC
Arm Type
Experimental
Arm Description
patients receiving efgartigimod PH20 SC on top of prednisone
Intervention Type
Biological
Intervention Name(s)
efgartigimod PH20 SC
Intervention Description
Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
Intervention Type
Drug
Intervention Name(s)
prednisone
Intervention Description
Oral prednisone tablets
Primary Outcome Measure Information:
Title
Incidence of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE)
Description
Incidence of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE)
Time Frame
Up to 60 weeks
Title
Severity of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE)
Description
Severity of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE)
Time Frame
Up to 60 weeks
Secondary Outcome Measure Information:
Title
Proportion of Pemphigus Vulgaris (PV) participants who achieve complete clinical remission (CR) on minimal prednisone therapy
Description
Proportion of participants with Pemphigus Vulgaris who achieve complete clinical remission on minimal prednisone therapy.
Time Frame
Up to 52 weeks treatment period
Title
Proportion of Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) participants who achieve complete clinical remission (CR) on minimal prednisone dose therapy
Description
Proportion of participants with Pemphigus Vulgaris and Pemphigus Foliaceus who achieve complete clinical remission on minimal prednisone therapy.
Time Frame
Up to 52 weeks treatment period
Title
Time to Disease Control (DC)
Description
Time to Disease Control
Time Frame
Up to 60 weeks
Title
Time to complete clinical remission (CR)
Description
Time to complete clinical remission
Time Frame
Up to 60 weeks
Title
Time to complete clinical remission (CR) on minimal prednisone therapy
Description
Time to complete clinical remission on minimal prednisone therapy
Time Frame
Up to 60 weeks
Title
Time to complete clinical remission (CR) off prednisone therapy
Description
Time to complete clinical remission off prednisone therapy
Time Frame
Up to 60 weeks
Title
Time to flare
Description
Time to flare
Time Frame
Up to 60 weeks
Title
Rate of treatment failure
Description
Rate of treatment failure
Time Frame
Up to 60 weeks
Title
Rate of flare
Description
Rate of flare
Time Frame
Up to 60 weeks
Title
Cumulative prednisone dose over the trial
Description
Cumulative prednisone dose over the trial
Time Frame
Up to 52 weeks treatment period
Title
Pemphigus Disease Area Index (PDAI) at each visit
Description
Pemphigus Disease Area Index at each visit
Time Frame
Up to 52 weeks treatment period
Title
EuroQol 5-Dimension 5-Level (EQ-5D-5L) score
Description
EuroQol 5-Dimension 5-Level score
Time Frame
Up to 52 weeks treatment period
Title
Autoimmune Blister Quality of Life (ABQOL) score
Description
Autoimmune Blister Quality of Life score
Time Frame
Up to 52 weeks treatment period
Title
Efgartigimod serum concentrations
Description
Efgartigimod serum concentrations
Time Frame
Up to 60 weeks
Title
Total Immunoglobulin G and subtype (IgG1, IgG2, IgG3, IgG4) serum levels
Description
Total Immunoglobulin G and subtype (IgG1, IgG2, IgG3, IgG4) serum levels
Time Frame
Up to 60 weeks
Title
Anti-desmoglein (Dsg) -1 and -3 autoantibodies serum levels
Description
Anti-desmoglein (Dsg) -1 and -3 autoantibodies serum levels
Time Frame
Up to 60 weeks
Title
Incidence of antidrug antibodies (ADA) against efgartigimod PH20 SC
Description
Incidence of antidrug antibodies (ADA) against efgartigimod PH20 SC
Time Frame
Up to 60 weeks
Title
Prevalence of antidrug antibodies (ADA) against efgartigimod PH20 SC
Description
Prevalence of antidrug antibodies (ADA) against efgartigimod PH20 SC
Time Frame
Up to 60 weeks
Title
Composite Glucocorticoid Toxicity Index (C-GTI) comprising the Aggregate Improvement Score (AIS) and the Cumulative Worsening Score (CWS)
Description
Composite Glucocorticoid Toxicity Index comprising the Aggregate Improvement Score and the Cumulative Worsening Score
Time Frame
Up to 52 weeks treatment period
Title
Percentage of participants who performed self-administration
Description
Percentage of participants who performed self-administration
Time Frame
Up to 52 weeks
Title
Percentage of caregivers who administered the injection to the participant
Description
Percentage of caregivers who administered the injection to the participant
Time Frame
Up to 52 weeks
Title
Number of visits needed for the participant or caregiver to be competent to start administering efgartigimod PH20 SC
Description
Number of visits needed for the participant or caregiver to be competent to start administering efgartigimod PH20 SC
Time Frame
Up to 52 weeks
Title
Frequency of self- or caregiver-supported administration at home
Description
Frequency of self- or caregiver-supported administration at home
Time Frame
Up to 52 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ability to understand the requirements of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), willingness and ability to comply with the trial protocol procedures (including required trial visits). The participant participated in trial ARGX-113-1904 and completed the study or has the defined criteria for rollover. Contraceptive use by men and women should be consistent with local regulations regarding the methods for contraception for those participating in clinical trials and: Male participants: Male participants must agree to use an acceptable method of contraception as described in the protocol, from signing the ICF until the last dose of the study drug. Female participants Women of childbearing potential (WOCBP) must: have a negative urine pregnancy test at baseline before the IMP can be administered, agree to use a highly effective or acceptable contraception method (as described in the protocol), which should be maintained at minimum until after the last dose of IMP Exclusion Criteria: Pregnant and lactating women and those intending to become pregnant during the trial. Participants with clinical evidence of other significant serious disease or participants who recently underwent or have planned a major surgery during the period of the trial, or any other condition in the opinion of the investigator, that could confound the results of the trial or put the participant at undue risk. Known hypersensitivity to any of the components of the administered treatments.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Ext
+1
Email
clinicaltrials@argenx.com
Facility Information:
Facility Name
Investigator site 115 - US0010086
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 89 - US0010091
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85259
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 124 - US0010092
City
Redwood City
State/Province
California
ZIP/Postal Code
94063
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
Clinicaltrials@argenx.com
Facility Name
Investigator site 1 - US0010087
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33428
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 90 - US0010117
City
Miami
State/Province
Florida
ZIP/Postal Code
33173
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 91 - US0010109
City
Orlando
State/Province
Florida
ZIP/Postal Code
32827
Country
United States
Individual Site Status
Completed
Facility Name
Investigator site 126 - US0010090
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Individual Site Status
Completed
Facility Name
Investigator site 111 - US0010098
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 10 - US0010088
City
Buffalo
State/Province
New York
ZIP/Postal Code
14203-1070
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 76 - US0010096
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 30 - US0010094
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106-1716
Country
United States
Individual Site Status
Completed
Facility Name
Investigator site 84 - US0010089
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Completed
Facility Name
Investigator site 103 - US0010097
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19140
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 125 - US0010107
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Individual Site Status
Completed
Facility Name
Investigator site 87 - US0010084
City
Dripping Springs
State/Province
Texas
ZIP/Postal Code
78620
Country
United States
Individual Site Status
Completed
Facility Name
Investigator site 88 - US0010114
City
Houston
State/Province
Texas
ZIP/Postal Code
77008
Country
United States
Individual Site Status
Completed
Facility Name
Investigator site 44 - US0010106
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23502
Country
United States
Individual Site Status
Completed
Facility Name
Investigator site 15 - AU0610006
City
Sydney
State/Province
New South Wales
ZIP/Postal Code
2217
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 11 - AU0610007
City
Parkville
State/Province
Victoria
ZIP/Postal Code
3050
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 92 - AU0610013
City
Melbourne
ZIP/Postal Code
3065
Country
Australia
Individual Site Status
Completed
Facility Name
Investigator site 17 - BG3590012
City
Pleven
ZIP/Postal Code
5800
Country
Bulgaria
Individual Site Status
Completed
Facility Name
Investigator site 18 - BG3590013
City
Plovdiv
ZIP/Postal Code
4000
Country
Bulgaria
Individual Site Status
Completed
Facility Name
Investigator site 2 - BG3590010
City
Sofia
ZIP/Postal Code
1431
Country
Bulgaria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 16 - BG3590009
City
Sofia
ZIP/Postal Code
1510
Country
Bulgaria
Individual Site Status
Completed
Facility Name
Investigator site 3 - BG3590011
City
Sofia
ZIP/Postal Code
1606
Country
Bulgaria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 101 - CN0860017
City
Beijing
ZIP/Postal Code
100034
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 107 - CN0860018
City
Chengdu
ZIP/Postal Code
610000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 118 - CH0860027
City
Chongqing
ZIP/Postal Code
400042
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 120 - CH0860023
City
Fuzhou
ZIP/Postal Code
35005
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 119 - CH0860022
City
Guangzhou
ZIP/Postal Code
510000
Country
China
Individual Site Status
Completed
Facility Name
Investigator site 116 - CH0860053
City
Guangzhou
ZIP/Postal Code
51000
Country
China
Individual Site Status
Completed
Facility Name
Investigator site 100 - CN0860021
City
Guanzhou
ZIP/Postal Code
510000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 113 - CN0860024
City
Nanjing
ZIP/Postal Code
210042
Country
China
Individual Site Status
Completed
Facility Name
Investigator site 102 - CN0860020
City
Shanghai
ZIP/Postal Code
200025
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 99 - CN0860016
City
Shanghai
ZIP/Postal Code
200040
Country
China
Individual Site Status
Completed
Facility Name
Investigator site 112 - CN0860019
City
Wuhan
ZIP/Postal Code
430022
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 121 - CH0860025
City
Wuhan
ZIP/Postal Code
430022
Country
China
Individual Site Status
Completed
Facility Name
Investigator site 117 - CH0860026
City
Zhengzhou
ZIP/Postal Code
450008
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 77 - FR0330028
City
Bobigny
ZIP/Postal Code
93000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 60 - FR0330027
City
La Tronche
ZIP/Postal Code
38700
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 108 - FR0330029
City
Rouen
ZIP/Postal Code
76031
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 51 - FR0330026
City
Saint-Étienne
ZIP/Postal Code
42055
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 78 - GE9950014
City
Tbilisi
ZIP/Postal Code
0159
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 127 - GE9950030
City
Tbilisi
ZIP/Postal Code
0160
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
Clinicaltrials@argenx.com
Facility Name
Investigator site 32 - GE9950013
City
Tbilisi
ZIP/Postal Code
0162
Country
Georgia
Individual Site Status
Completed
Facility Name
Investigator site 31 - GE9950015
City
Tbilisi
ZIP/Postal Code
0179
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 45 - DE0490029
City
Berlin
ZIP/Postal Code
10117
Country
Germany
Individual Site Status
Completed
Facility Name
Investigator site 34 - DE0490030
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 33 - DE0490024
City
Frankfurt am main
ZIP/Postal Code
60590
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 53 - DE0490023
City
Freiburg
ZIP/Postal Code
79104
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 35 - DE0490028
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 20 - DE0490002
City
Lübeck
ZIP/Postal Code
23538
Country
Germany
Individual Site Status
Completed
Facility Name
Investigator site 52 - DE0490001
City
Marburg
ZIP/Postal Code
35043
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 19 - DE0490025
City
Tübingen
ZIP/Postal Code
72076
Country
Germany
Individual Site Status
Completed
Facility Name
Investigator site 93 - DE0490027
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Individual Site Status
Completed
Facility Name
Investigator site 4 - DE0490026
City
Würzburg
ZIP/Postal Code
97080
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-357-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 21 - GR030004
City
Athens
ZIP/Postal Code
11525
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 37 - GR030006
City
Athens
ZIP/Postal Code
16121
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 54 - GR0300001
City
Athens
ZIP/Postal Code
16121
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 22 - GR030003
City
Chaïdári
ZIP/Postal Code
12462
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 36 - GR0300002
City
Thessaloníki
ZIP/Postal Code
54643
Country
Greece
Individual Site Status
Completed
Facility Name
Investigator site 23 - GR030005
City
Thessaloníki
ZIP/Postal Code
56429
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 6 - HU0360003
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 5 - HU0360001
City
Pécs
ZIP/Postal Code
7632
Country
Hungary
Individual Site Status
Completed
Facility Name
Investigator site 24 - HU0360002
City
Szeged
ZIP/Postal Code
6720
Country
Hungary
Individual Site Status
Completed
Facility Name
Investigator site 65 - IN0910002
City
Ahmedabad
ZIP/Postal Code
380016
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 94 - IN0910001
City
Chandigarh
ZIP/Postal Code
160012
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 79 - IN0910004
City
Lucknow
ZIP/Postal Code
226005
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 80 - IN0910003
City
Nagpur
ZIP/Postal Code
440003
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 85 - IL9720002
City
Tel Aviv
ZIP/Postal Code
64239
Country
Israel
Individual Site Status
Completed
Facility Name
Investigator site 95 - IT0390039
City
Catania
ZIP/Postal Code
95123
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 38 - IT0390031
City
Firenze
ZIP/Postal Code
50125
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 81 - IT0390030
City
Genova
ZIP/Postal Code
16132
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 55 - IT0390038
City
Perugia
ZIP/Postal Code
06129
Country
Italy
Individual Site Status
Completed
Facility Name
Investigator site 12 - IT0390006
City
Roma
ZIP/Postal Code
00167
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 25 - IT-0390005
City
Roma
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 61 - IT0390040
City
Siena
ZIP/Postal Code
53100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 82 - JP0810046
City
Aichi
ZIP/Postal Code
480-1195
Country
Japan
Individual Site Status
Completed
Facility Name
Investigator site 68 - JP0810040
City
Hiroshima
ZIP/Postal Code
734-8551
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 69 - JP0810050
City
Kurume
ZIP/Postal Code
830-001
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 66 - JP0810042
City
Kōfu
ZIP/Postal Code
400-8506
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 73 - JP0810047
City
Okayama
ZIP/Postal Code
700-8558
Country
Japan
Individual Site Status
Completed
Facility Name
Investigator site 70 - JP0810041
City
Okayama
ZIP/Postal Code
701-0192
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 71 - JP0810049
City
Osaka
ZIP/Postal Code
545-8586
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 72 - JP0810045
City
Sapporo
ZIP/Postal Code
060-8648
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 114 - JP0810067
City
Sendai
ZIP/Postal Code
980-8574
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 67 - JP0810043
City
Tokyo
ZIP/Postal Code
113-8431
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 27 - PL0480027
City
Katowice
ZIP/Postal Code
40-081
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 86 - PL0480036
City
Poznań
ZIP/Postal Code
60-369
Country
Poland
Individual Site Status
Completed
Facility Name
Investigator site 28 - PL0480025
City
Rzeszów
ZIP/Postal Code
35-055
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 26 - PL0480028
City
Wrocław
ZIP/Postal Code
50-566
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 56 - PL0480032
City
Łódź
ZIP/Postal Code
90-647
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 97 - RO0400013
City
Bucharest
ZIP/Postal Code
011216
Country
Romania
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator 96 - RO0400014
City
Cluj-Napoca
ZIP/Postal Code
400006
Country
Romania
Individual Site Status
Completed
Facility Name
Investigator site 98 - RO0400015
City
Iaşi
ZIP/Postal Code
700111
Country
Romania
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 40 - RU0070035
City
Chelyabinsk
ZIP/Postal Code
454092
Country
Russian Federation
Individual Site Status
Completed
Facility Name
Investigator site 41 - RU0070033
City
Ekaterinburg
ZIP/Postal Code
620076
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 48 - RU0070029
City
Kazan
ZIP/Postal Code
420111
Country
Russian Federation
Individual Site Status
Completed
Facility Name
Investigator site 49 - RU0070030
City
Krasnodar
ZIP/Postal Code
350020
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 39 - RU0070032
City
Rostov-on-Don
ZIP/Postal Code
344002
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 46 - RU0070031
City
Saint Petersburg
ZIP/Postal Code
191123
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 50 - RU0070034
City
Saint Petersburg
ZIP/Postal Code
197022
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 47 - RU0070028
City
Saratov
ZIP/Postal Code
410012/410028
Country
Russian Federation
Individual Site Status
Completed
Facility Name
Investigator site 109 - RS3810011
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Individual Site Status
Completed
Facility Name
Investigator site 110 - RS3810010
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Individual Site Status
Completed
Facility Name
Investigator site 105 - RS3810012
City
Niš
ZIP/Postal Code
18000
Country
Serbia
Individual Site Status
Completed
Facility Name
Investigator site 104 - RS3810009
City
Novi Sad
ZIP/Postal Code
21000
Country
Serbia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 62 - ES0340026
City
Barcelona
ZIP/Postal Code
08907
Country
Spain
Individual Site Status
Completed
Facility Name
Investigator site 13 - ES0340032
City
Barcelona
ZIP/Postal Code
8036
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 122 - ES0340053
City
Granada
ZIP/Postal Code
18016
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
Clinicaltrials@argenx.com
Facility Name
Investigator site 59 - ES0340034
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Individual Site Status
Completed
Facility Name
Investigator site 42 - ES0340025
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Completed
Facility Name
Investigator site 7 - ES0340029
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 57 - ES0340027
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Individual Site Status
Completed
Facility Name
Investigator site 58 - ES0340028
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Completed
Facility Name
Investigator site 64 - TR0900020
City
Gaziantep
ZIP/Postal Code
27310
Country
Turkey
Individual Site Status
Completed
Facility Name
Investigator site 63 - TR0900012
City
Istanbul
ZIP/Postal Code
34098
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 74 - TR0900011
City
Istanbul
ZIP/Postal Code
34722
Country
Turkey
Individual Site Status
Completed
Facility Name
Investigator site 75 - UA3800017
City
Dnipro
ZIP/Postal Code
49074
Country
Ukraine
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 29 - UA3800023
City
Ivano-Frankivs'k
ZIP/Postal Code
76018
Country
Ukraine
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 14 - UA3800020
City
Kyiv
ZIP/Postal Code
04050
Country
Ukraine
Individual Site Status
Completed
Facility Name
Investigator site 8 - UA3800019
City
Kyiv
ZIP/Postal Code
4209
Country
Ukraine
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 43 - UA3800021
City
Lviv
ZIP/Postal Code
79013
Country
Ukraine
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 9 - UA3800018
City
Zaporizhzhia
ZIP/Postal Code
69063
Country
Ukraine
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 106 - UK0440021
City
Birmingham
ZIP/Postal Code
B15 2GW
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 83 - UK0440022
City
Bristol
ZIP/Postal Code
BS2 8HW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Coppieters, MD
Phone
857-350-4834
Email
clinicaltrials@argenx.com
Facility Name
Investigator site 123 - UK0440037
City
Southampton
ZIP/Postal Code
SO16 6YD
Country
United Kingdom
Individual Site Status
Completed

12. IPD Sharing Statement

Learn more about this trial

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

We'll reach out to this number within 24 hrs